All articles by Abigail Beaney

Abigail Beaney

Abigail Beaney is the editor of Clinical Trials Arena. Abigail has expertise in clinical trial regulation, trial design, outsourcing, and cell and gene therapies. Abigail also has covered news and has a wealth of knowledge across several therapy areas including neurodegenerative, infectious and metabolic diseases. Abigail holds a first-class BA (Hons) degree in Journalism from the University of Central Lancashire in the United Kingdom. She has also obtained the National Qualification in Journalism through the UK's media industry body, the National Council for the Training of Journalists. Contact Abigail

Pharma positions itself for 2026 amid an evolving US landscape

After President Donald Trump’s administration took office in early 2025, a series of policy changes have directly impacted the pharma…
Takeda to seek approval of plaque psoriasis pill on Phase III trial data

Takeda’s once-daily oral plaque psoriasis (PsO) drug has met all its endpoints in two pivotal trials, with the company set…
Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA

Pfizer has confirmed another push into the obesity market in the form of a licencing deal worth up to approximately…
Potentially “groundbreaking” FDA gene therapy pathway leaves key issues unresolved

The US Food and Drug Administration’s (FDA’s) new pathway for gene therapies could be “groundbreaking” if applied broadly, though the…
EuropaBio calls for “bold approach to investment” amid EU Biotech Act

Amid the European Commission’s (EC’s) public consultation on the EU Biotech Act, EuropaBio has called for the EU to adopt…

Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by…
Novo Nordisk and Pfizer’s bidding war for Metsera escalates despite legal threats

Novo Nordisk has raised its offer to buy out obesity biotech Metsera to $10bn as a bidding war with Pfizer…
Aldeyra reshuffles pipeline, culling asset despite Phase II success

Aldeyra Therapeutics has reshuffled its pipeline, terminating the development of a Phase II asset despite meeting its endpoints in alcohol-associated…
Lilly and Incyte to seek approval of alopecia JAK inhibitor in children

Eli Lilly and Incyte’s oral JAK inhibitor has shown benefit in hair regrowth in paediatric patients with severe alopecia areata.…
Pharma R&D set to endure despite rising MFN costs

Pharmaceutical research and development (R&D) is unlikely to be significantly impacted by most favored nation (MFN) pricing, according to industry…